Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether control of inflammatory pathways mediated
by IL-1 beta using the IL-1 receptor antagonist anakinra will yield measurable decreases in
expression of genes that are otherwise overexpressed as a consequence of IL-1 beta effects in
children with newly diagnosed type 1 diabetes. Ultimately, we believe that control of IL-1
beta pathways will be associated with preserved insulin secretory capacity.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborator:
Children's Medical Center Dallas
Treatments:
Anti-Inflammatory Agents Interleukin 1 Receptor Antagonist Protein